Argenx (ARGX)
NASDAQ:ARGX
Want to see ARGX full AI Analyst Report?
ARGX Stock Chart & Stats
$849.04
$8.96(1.38%)
At close: 4:00 PM EST
$849.04
$8.96(1.38%)
Day’s Range― - ―
52-Week Range$510.06 - $934.62
Previous CloseN/A
Volume151.62K
Average Volume (3M)318.14K
Market Cap
$50.82B
Enterprise Value$46.92B
Total Cash (Recent Filing)$4.44B
Total Debt (Recent Filing)$83.49M
Price to Earnings (P/E)39.9
Beta0.33
Next Earnings
Jul 23, 2026EPS Estimate
6.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)21.10
Shares Outstanding61,883,408
10 Day Avg. Volume334,911
30 Day Avg. Volume318,139
Financial Highlights & Ratios
PEG Ratio0.77
Price to Book (P/B)7.04
Price to Sales (P/S)12.41
P/FCF Ratio61.05
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue11.28
Enterprise Value/Gross Profit12.72
Enterprise Value/Ebitda47.00
Forecast
1Y Price Target
$1,038.01Price Target Upside22.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)26.85
Revenue Forecast (FY)$5.96B
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionVyvgart's rapid uptake driven by prefilled syringe availability and a growing prescriber base supports sustained sales growth and reinforces its position as a leading biologic for myasthenia gravis.
Pipeline DiversificationAdvancement of empasiprubart and multiple late-stage immunology candidates provides a path to a second commercial product and diversifies revenue beyond the core Vyvgart franchise.
Regulatory And Label ExpansionPositive Phase III results in ocular myasthenia gravis underpin plans for regulatory submission and label expansion into ocular and seronegative populations, which would increase the addressable patient pool and encourage earlier treatment prescribing.
Bears Say
Clinical Development RiskScientific complexity in indications such as systemic sclerosis and immune thrombocytopenia raises development risk and could limit upside if pivotal trials do not meet endpoints.
Market Sentiment And Valuation PressureShares underperforming peer biotech companies despite positive clinical and commercial updates suggests investor skepticism that could weigh on valuation until growth proves durable.
Pipeline SetbacksDiscontinuation of the amyotrophic lateral sclerosis program after unsuccessful trial results represents a material pipeline setback and reduces the number of near-term clinical catalysts.
Argenx Se News
ARGX FAQ
What was Argenx’s price range in the past 12 months?
Argenx lowest stock price was $510.06 and its highest was $934.62 in the past 12 months.
What is Argenx’s market cap?
Argenx’s market cap is $50.82B.
When is Argenx’s upcoming earnings report date?
Argenx’s upcoming earnings report date is Jul 23, 2026 which is in 56 days.
How were Argenx’s earnings last quarter?
Argenx released its earnings results on May 07, 2026. The company reported $5.52 earnings per share for the quarter, beating the consensus estimate of $5.378 by $0.142.
Is Argenx overvalued?
According to Wall Street analysts Argenx’s price is currently Undervalued.
Does Argenx pay dividends?
Argenx does not currently pay dividends.
What is Argenx’s EPS estimate?
Argenx’s EPS estimate is 6.34.
How many shares outstanding does Argenx have?
Argenx has 61,883,408 shares outstanding.
What happened to Argenx’s price movement after its last earnings report?
Argenx reported an EPS of $5.52 in its last earnings report, beating expectations of $5.378. Following the earnings report the stock price went down -2.506%.
Which hedge fund is a major shareholder of Argenx?
Currently, no hedge funds are holding shares in ARGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenx Se Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,038.01 (22.26% Upside)
$1,038.01 (22.26% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 128.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.57%
12-Months-Change
Fundamentals
Return on Equity
16.82%
Trailing 12-Months
Asset Growth
39.99%
Trailing 12-Months
Company Description
Argenx
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
ARGX Company Deck
ARGX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive commercial and financial picture: exceptional revenue growth (+90% YoY), first full-year operating profitability, a robust cash position (+>$1B YoY), and an expanding patient base (≈19,000). Clinically, the positive Phase III ADAPT OCULUS ocular MG readout (p=0.012; mean improvement 4.04 vs 1.99) and recent seronegative data (with a PDUFA in May) materially expand VYVGART’s addressable market and support label expansion. The company also highlighted a deepening pipeline and strategic investments in next-generation FcRn assets. Offsetting factors include a low gross margin (~11%), significant OpEx and R&D spend (combined R&D+SG&A $2.7B; ~30% YoY increase), a failed ALS study that halts that program, regulatory requests increasing trial burden in Graves, and payer/timing uncertainties that could delay realization of some label expansion benefits. Overall, the positive commercial momentum, profitability milestone, and major clinical win for ocular MG outweigh the challenges and near-term risks.View all ARGX earnings summariesARGX Stock 12 Month Forecast
Average Price Target
$1,038.01
▲(22.26% Upside)
Technical Analysis
Ownership Overview
―
Insiders
20.10% Mutual Funds
15.35% Other Institutional Investors
63.04% Public Companies and Individual Investors